Tivozanib
Overview
Tivozanib is a potent and selective inhibitor of vascular endothelial growth factor receptors (VEGFRs), designed to inhibit angiogenesis for the treatment of renal cell carcinoma. It is effective in blocking tumor angiogenesis, thereby reducing blood supply to the tumor.
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Tivozanib expires 5 Nov 2039 and exclusivity 10 Mar 2026. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Tivozanib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.